Ticker: TSX – TOS
Shares Outstanding: 73,324,656
QUÉBEC CITY, Sept. 19, 2014 /CNW Telbec/ - TSO3 Inc. (TSX: TOS) ("TSO3" or the "Corporation") an innovator in sterilization technology for medical devices in healthcare settings, today announced that the Company has officially submitted its response to the US Regulatory Authorities request for Additional Information. The response allows the Regulatory Authorities to continue their review for market clearance of the TSO3 STERIZONE® VP4 Sterilizer in the United States.
"In August of this year, we stated that our response to the Additional Information request would take up to eight weeks to complete", stated R.M (Ric) Rumble President and CEO. "As it turns out, we were able to collect the information and formulate answers to their questions in a shorter period of time. With our response now in the Regulators possession, we feel we are reaching the final phase of the process, which is labeling review. We continue to expect a positive outcome of this files review", concluded Mr. Rumble.
TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. TSO3 designs products for sterile processing areas in the hospital environment and offers an advantageous replacement solutions to other low temperature sterilization processes currently used in hospitals.
For more information about TSO3, visit the Company's Web site at www.tso3.com
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
SOURCE: TSO3 Inc.
For further information: R.M. (Ric) Rumble, President and CEO, (418) 651-0003, Ext. 254, Email: [email protected]